Chan Alex H P, Huang Ngan F
Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, United States.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, United States.
Front Bioeng Biotechnol. 2021 Apr 20;9:673212. doi: 10.3389/fbioe.2021.673212. eCollection 2021.
In recent years, the cost of drug discovery and development have been progressively increasing, but the number of drugs approved for treatment of cardiovascular diseases (CVDs) has been limited. Current models for drug development do not sufficiently ensure safety and efficacy, owing to their lack of physiological relevance. On the other hand, preclinical animal models are extremely costly and present problems of inaccuracy due to species differences. To address these limitations, tissue chips offer the opportunity to emulate physiological and pathological tissue processes in a biomimetic platform. Tissue chips enable modeling of CVDs to give mechanistic insights, and they can also be a powerful approach for drug screening applications. Here, we review recent advances in CVD modeling using tissue chips and their applications in drug screening.
近年来，药物研发的成本一直在逐步增加，但获批用于治疗心血管疾病（CVD）的药物数量却很有限。由于目前的药物研发模型缺乏生理相关性，因此无法充分确保安全性和有效性。另一方面，临床前动物模型成本极高，并且由于物种差异存在准确性问题。为了解决这些局限性，组织芯片提供了在仿生平台上模拟生理和病理组织过程的机会。组织芯片能够对心血管疾病进行建模以提供机制性见解，并且它们也可以成为药物筛选应用的有力方法。在此，我们综述了使用组织芯片进行心血管疾病建模的最新进展及其在药物筛选中的应用。
